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Abstract: Group B coxsackieviruses (CVBs) belonging to the genus, Enterovirus and contain six
serotypes that induce various diseases, whose occurrence may involve the mediation of more than
one serotype. We recently identified immunogenic epitopes within coxsackieviruses B3 (CVB3)
viral protein 1 that induce anti-viral T cell responses in mouse models of CVB infections. In our
investigations to determine the protective responses of the viral epitopes, we unexpectedly noted
that animals immunized with complete Freund’s adjuvant (CFA) alone and later challenged with
CVB3 were completely protected against myocarditis. Similarly, the pancreatitis-inducing ability of
CVB3 was remarkably reduced to only 10% in the CFA group as opposed to 73.3% in the control
group that received no CFA. Additionally, no mortalities were noted in the CFA group, whereas
40% of control animals died during the course of 21 days post-infection with CVB3. Taken together,
our data suggest that the adjuvant effects of CFA may be sufficient for protection against CVB
infections. These observations may provide new insights into our understanding of the occurrence of
viral infections.
Keywords: enterovirus; adjuvant; CFA; BCG
1. Introduction
Enteroviruses belonging to the Picornaviridae family are positive-sense, single-stranded RNA
viruses. Based on the currently-adopted method of molecular typing of the viral protein 1 (VP1)
nucleotide composition, 13 species of enteroviruses have been identified [1]. Infections caused by four
enterovirus species, enterovirus A to D, are the most common that occur in humans, especially infants
(children less than 1 year of age) and immune-compromised individuals [1,2]. Enteroviruses induce a
wide spectrum of illnesses, such as meningitis, encephalitis, paralysis, myocarditis, and rash/foot and
mouth disease [2]. Although enteroviral infections can occur anywhere in the world, recent outbreaks
of respiratory illness in the United States highlight their growing importance in human health [3–5].
We have been studying the cellular and molecular mechanisms of protective immune responses in
mouse models, particularly for coxsackieviruses B3 (CVB3) and B4 (CVB4), which are implicated in the
causation of myocarditis/dilated cardiomyopathy and Type I diabetes (TID), respectively [6,7]. We have
identified three T cell epitopes within the VP1 of CVB3 namely, VP1 681–700, VP1 721–740, and VP1
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771–790. We demonstrated that these epitopes bind major histocompatibility-complex class II molecules
with varied affinities [8], that can be used to assess antigen-specific T cell responses in infection or
vaccine studies. Traditionally, complete Freund’s adjuvant (CFA) is used to assess the immunogenicity
of antigens [9], but it is unclear whether adjuvant effects of CFA alone can offer protection against
CVB3 because mycobacterial components in CFA can mediate anti-viral responses [10,11]. In this
report, we sought to determine the effect of CFA on CVB3 infection in highly susceptible A/J mice and
made an unexpected observation that the animals immunized with CFA were found to be completely
protected from both myocarditis and pancreatitis induced with CVB3.
2. Materials and Methods
2.1. Mice
Six-to-eight-week old, female A/J mice (H-2a) were procured from the Jackson Laboratory (Bar
Harbor, ME, USA). Animals were maintained according to the institutional guidelines of the University
of Nebraska–Lincoln (UNL), Lincoln, NE, and approval for animal studies was granted by the
Institutional Animal Care and Use Committee, UNL (protocol #1904, approved 2 January 2020).
Mice infected with CVB3 were monitored closely for clinical signs suggestive of distress. All research
staff followed biosafety level 2 guidelines while handling the animals. Animals whose clinical
signs persisted, did not eat or drink, and failed to move when touched or prodded physically were
immediately euthanized. Euthanasia was performed using a carbon dioxide chamber as recommended
by the Panel on Euthanasia, the American Veterinary Medical Association.
2.2. Virus Propagation and Infection
The Nancy strain of CVB3 was procured from the American Type Culture Collection (ATCC,
Manassas, VA, USA), and the virus was titrated in Vero cells (ATCC). The adherent Vero cells were
grown to 80 to 90% confluence in 75cm2 flasks in Eagle’s minimum essential medium (EMEM)/10%
fetal bovine serum (FBS) and were later infected with CVB3 with multiplicity of infection 1 in EMEM
containing no FBS. After incubation at 37 ◦C for 1 hour with gentle intermittent rocking, maintenance
medium (EMEM/2% FBS) was added. Based on the cytopathic effect of virus during the next 1 to 2 days,
supernatants containing virus were harvested. After determining 50% tissue culture infective dose
(TCID50) values based on the Reed–Muench method, the virus stocks were aliquoted and preserved
at −80 ◦C [12]. To infect mice, virus stock diluted in 1× PBS to contain 50 TCID50 in 100 µL was
administered intraperitoneally (i.p.). We chose this dose based on titration experiments [12] that allowed
us to capture pathological changes in both heart and pancreas over a period of 3 weeks by avoiding
acute mortalities that usually occur at relatively higher doses within ~10 days post-infection [13,14].
Animals were monitored closely, cages were changed once in 2 days, and body weights were taken
daily until termination. In addition, an alternative food and fluid source, trans gel diet (ClearH2O,
Portland, ME, USA), was placed on the cage floor as needed.
2.3. Challenge Studies in Animals Immunized with CFA
To investigate the effects of CFA on CVB3 infection, we used CFA that contained heat-killed
Mycobacterium tuberculosis (M. tb), paraffin oil and mannose monooleate (Difco Laboratories, Detroit,
MI, USA) [8,15]. Groups of animals were immunized subcutaneously with or without CFA emulsion
(200 µL; Sigma-Aldrich, St. Louis, MO, USA) containing 5 mg/mL of M. tb to a final concentration of
2.5 mg/mL in 1× PBS as a single dose on day −7 in sternal and inguinal regions [16]. Essentially, 200 µL
of CFA emulsion contained 500 µg of M. tb extract. Seven days later (day 0), animals were challenged
with CVB3 at 50 TCID50/mouse, i.p., and after taking body weights and monitoring for mortalities,
experiments were terminated on days 20–21 post-infection and tissues were collected for histology.
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2.4. Histology
Hearts and pancreata were fixed in 10% phosphate-buffered formalin and processed to obtain
5 µm thick serial sections, ~50 µm apart. All sections were stained by hematoxylin and eosin (H and E).
The analysis was performed by a board-certified pathologist blinded to treatment, and total number of
inflammatory foci were obtained as reported previously [12,17].
2.5. Statistics
Generalized linear mixed models were used to analyze the data pertaining to body weights
and survival curves using Proc Glimmix in SAS (Version 9.3, SAS Institute Inc., Cary, NC, USA).
Graphs were prepared by GraphPad Prism software Version 8.0 (GraphPad Software, Inc. La Jolla, CA,
USA). Barnard’s exact test was used to analyze the histological parameters [18].
3. Results and Discussion
In this report, we provide evidence that immunization with immune-stimulating adjuvants
like CFA alone can offer protection against viral infections. In this setting, we used A/J mice that
are highly susceptible to CVB infections, with affected animals showing severe pancreatitis and
myocarditis within approximately 7 to 10 days post-infection [8,17,19]. Although our primary focus
was to determine whether viral peptides can offer protection in challenge studies with CVB3, we made
an unexpected observation that the protection offered by CFA emulsions containing viral peptides
was indistinguishable (data not shown) from that conferred by immunization with CFA alone. First,
we noted that the positive control group (unimmunized) infected with CVB3 showed reduction in
body weights by ~20% as expected, whereas none of the animals immunized with CFA alone lost body
weight (Figure 1, left panel). Second, mortality patterns were also found to be similar to those of body
weights, in that none of the animals immunized with CFA alone died, whereas 40% of animals (6/15) in
the control group died (Figure 1, right panel), pointing to the possibility that CFA-immunized animals
would also be free of histologic disease.
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Figure 1. Evaluation of effects of complete Freund’s adjuvant (CFA) in coxsackieviruses B3 (CVB3)
infection of A/J mice. (a) A/J mice were immunized once (day −7) with or without CFA alone and were
challenged with CVB3 on day 0. Body weights were taken up to 20 days post-challenge with CVB3.
Mean ± SEM values obtained from two experiments, each involving 5 to 10 mice, are shown (left panel),
and (b) mortalities noted up to 21 days post-challenge are shown in the survival curves (right panel).
**** p ≤ 0.0001.
To investigate pathological changes, we examined the hearts and pancreata by H and E staining
and scored disease severity as we have described previously [12,16,17]. As indicated in Table 1,
top panel, and Figure 2, heart sections in 40% (6/15) of the animals from the CVB3-infected group
showed myocardial lesions containing inflammatory foci with macrophage infiltrates, necrosis,
and mineralization as expected [12,17], but none of the animals in the CFA group had any detectable
lesions. Similarly, histological evaluation of pancreatic sections from the CVB3-infected group revealed
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expected lesions such as atrophy, inflammation, necrosis, and mineralization, whereas in the CFA
group, only 10% (1/10) of the animals had detectable lesions (Table 1, bottom panel, and Figure 2).
Taken together, the findings that animals immunized with CFA alone were protected against both
myocarditis and pancreatitis induced with CVB3 supports the idea that non-specific priming of the
immune system with adjuvants like CFA may be sufficient to prevent virus infections.
Table 1. Histological evaluation of hearts and pancreata in mice immunized with or without CFA
challenged with CVB3.
Parameters CVB3 Group CFA + CVB3-Challenged Group
Myocarditis
Incidence 6/15 (40.0) 0/10 (0.0)
Inflammatory foci 54.4 ± 17.7 0.0
Pancreatitis
Incidence 11/15 (73.3) 1/10 (10.0)
Atrophy 7/15 (46.7) 1/10 (10.0)
Inflammation 11/15 (73.3) 1/10 (10.0)
Necrosis 8/15 (53.3) 0/10 (0.0)
Mineralization 4/15 (26.7) 1/10 (10.0)
() indicates percentages; all parameters were significant (p ≤ 0.01).
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Disease protection offered by CFA was rather perplexing to explain, because CFA was not
expected to induce antigen-specific immune responses to prevent infection with CVB3. Historically,
CFA containing M. tb has been used as a powerful immune-stimulating adjuvant, and it contains
immunoreactive molecules, such as N-acetylmuramyl-l-alanyl-d-isoglutamine (muramyl dipeptide)
and trehalose 6,6’-dimycolate, all of which promote T helper (Th) 1 cell polarization by inducing
interferon (IFN)-γ [10,11,20]. Reports indicate that the Bacillus Calmette–Guérin (BCG) containing
mycobacterium can enhance immunogenicity and also promote type I IFN response as shown in various
settings such as vaccinations against influenza and hepatitis B viruses in humans [21,22], and infection
studies with encephalomyocarditis, murine hepatitis (mouse coronavirus), type 1 and 2 herpes simplex,
vaccinia, and foot-and-mouth disease viruses in mice [23–28]. Additionally, bacterial CpG nucleotides
promote Th1 (IFN-γ) response [29], which is critical for protection against intracellular pathogens
and viruses through the production of interleukin-12 by interacting with toll-like receptor-9 [30,31].
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Thus, we believe that the disease-protective ability of CFA may reflect non-antigen-specific effects
attributable to the adjuvanticity of M. tb.
However, our data point to a few other possible mechanisms: (i) Exposure to non-specific
infections that promote Th1 cytokine responses may offer protection against viral infections possibly
by preventing viral replication [10,20,32]. If this holds true, then our data may also potentially provide
credence to the hygiene hypothesis [33,34]. (ii) A growing body of evidence suggests that the trained
innate memory may be an important property of the innate immune system. Myeloid cells, such as
monocytes and macrophages, natural killer (NK) cells, NK-T cells, γδ T cells, and possibly innate
lymphoid cells, exposed to a microbe—for example, ‘x’ microbe—can robustly respond to this microbe
upon re-exposure, and also for other unrelated microbial stimulations through epigenetic and metabolic
reprogramming pathways [35–37]. Consistent with this notion, it has been shown that BCG vaccine
can offer protection against other unrelated pathogens, such as Candida albicans, Schistosoma mansoni,
and Staphylococcus aureus [38–41], including autoimmune diseases such as Type I diabetes and multiple
sclerosis [42–46]. Likewise, an inverse relationship was observed between BCG vaccination and
severity of clinical disease resulting from severe respiratory syndrome coronavirus 2 infection [47,48].
Conversely, it is also possible that exposure to one type of pathogen can suppress immune responses
to entirely different types of pathogens. For example, co-administration of oral polio vaccine with
BCG at birth can diminish the response to purified protein derivative from BCG [49]. While the BCG
vaccine contains live Mycobacterium bovis (a pathogen of cattle), CFA contains the killed extract of
M. tb (a pathogen of humans). Yet all 13 known mycobacterial species, including the two species
identified above, show more than 99% nucleotide similarity, suggesting that all of them may have
similar adjuvant properties [50,51]. Furthermore, it has been recently demonstrated that the IFN-γ
response induced by BCG can facilitate epigenetic re-programming of hematopoietic stem cells in the
bone marrow towards a myeloid lineage that can initiate the central trained immunity in the bone
marrow against tuberculosis [52]. A suggestion has been made that the trained monocytes migrating
to peripheral tissues that give rise to macrophages can enhance immune responses to incoming/future
infections [36]. Since CFA promotes strong IFN-γ response similar to BCG [11], the protective effects of
CFA in CVB3 infection could be ascribed to IFN-γ. In support of this proposition, it has been shown
that the IFN-γ-deficient mice developed severe CVB3-induced myocarditis suggesting that IFN-γ
response plays a critical role in the prevention of CVB infections [53]. Similarly, mice immunized
with CFA were also found protected against vesicular stomatitis virus, and CFA-adjuvanted H1N1
influenza vaccine led to enhanced immune response in ferrets [54,55]. Although whether or not it is
currently known that trained innate memory is an underlying mechanism for CFA effects as noted in
our studies, this aspect may need to be investigated.
One limitation of our study is that we did not investigate the presence of virus in tissues
of CVB3-infected mice. Similarly, it is unknown whether CFA administration can potentiate the
production of protective neutralizing antibodies to CVB3, and if so, how long such an effect would
last against different doses of virus. Likewise, whether administration of CFA in the face of CVB3
infection can mitigate the disease process is also unknown. At the time of this writing, we could not
execute these experiments since our institutional guidelines do not allow any new animal experiments
because of the ongoing threat of coronavirus disease-19 pandemic to the public. Nonetheless, our
data may provide insights into our understanding of the occurrence of viral infections in the face of
pre-existing, non-antigen-specific immune responses generated in response to a potentially wide range
of environmental pathogens/microbes or gut microbiota over a period of time, which also may include
formation of virtual memory cells [56,57].
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